Drug Approval | April 11, 2025
Biocon Biologics announces USFDA approval for Jobevne biosimilar Bevacizumab
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis